Acne Vulgaris – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Acne Vulgaris – Pipeline Review, H1 2020’, provides an overview of the Acne Vulgaris pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acne Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Acne Vulgaris

– The report reviews pipeline therapeutics for Acne Vulgaris by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Acne Vulgaris therapeutics and enlists all their major and minor projects

– The report assesses Acne Vulgaris therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Acne Vulgaris

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allianz Pharmascience Ltd

Amgen Inc

AOBiome LLC

Avecho Biotechnology Ltd

Bausch Health Companies Inc

Biomimetix JV LLC

BioPharmX Inc

Boston Pharmaceuticals Inc

Botanix Pharmaceuticals Ltd

Boulos and Cooper Pharmaceuticals Pty Ltd

Cassiopea SpA

Cellix Bio Pvt Ltd

Cutanea Life Sciences Inc

Daewoong Co Ltd

Dermata Therapeutics LLC

Dermavant Sciences Inc

Devonian Health Group Inc

Eligo Bioscience SA

ELORAC Inc

Gage Development Company LLC

Galderma SA

Helix BioMedix Inc

Innovation Pharmaceuticals Inc

Johnson & Johnson

Kalytera Therapeutics Inc

Lee's Pharmaceutical Holdings Ltd

Melinta Therapeutics Inc

Menlo Therapeutics Inc

Mimetica Pty Ltd

Naked Biome Inc

Novabiotics Ltd

Novartis AG

Origimm Biotechnology GmbH

Ortho Dermatologics Inc

Phagelux Inc

PHI Therapeutics Inc

Photocure ASA

Promius Pharma LLC

Provectus Biopharmaceuticals Inc

Revive Therapeutics Ltd

Riptide Bioscience Inc

Sanotize Research And Development Corp

Sebela Pharmaceuticals Inc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Sol-Gel Technologies Ltd

Sun Pharma Advanced Research Company Ltd

Union Therapeutics AS

Verge Therapeutics Inc

Vyome Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Acne Vulgaris - Overview

Acne Vulgaris - Therapeutics Development

Acne Vulgaris - Therapeutics Assessment

Acne Vulgaris - Companies Involved in Therapeutics Development

Acne Vulgaris - Drug Profiles

Acne Vulgaris - Dormant Projects

Acne Vulgaris - Discontinued Products

Acne Vulgaris - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Acne Vulgaris, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Acne Vulgaris – Pipeline by Allianz Pharmascience Ltd, H1 2020

Acne Vulgaris – Pipeline by Amgen Inc, H1 2020

Acne Vulgaris – Pipeline by AOBiome LLC, H1 2020

Acne Vulgaris – Pipeline by Avecho Biotechnology Ltd, H1 2020

Acne Vulgaris – Pipeline by Bausch Health Companies Inc, H1 2020

Acne Vulgaris – Pipeline by Biomimetix JV LLC, H1 2020

Acne Vulgaris – Pipeline by BioPharmX Inc, H1 2020

Acne Vulgaris – Pipeline by Boston Pharmaceuticals Inc, H1 2020

Acne Vulgaris – Pipeline by Botanix Pharmaceuticals Ltd, H1 2020

Acne Vulgaris – Pipeline by Boulos and Cooper Pharmaceuticals Pty Ltd, H1 2020

Acne Vulgaris – Pipeline by Cassiopea SpA, H1 2020

Acne Vulgaris – Pipeline by Cellix Bio Pvt Ltd, H1 2020

Acne Vulgaris – Pipeline by Cutanea Life Sciences Inc, H1 2020

Acne Vulgaris – Pipeline by Daewoong Co Ltd, H1 2020

Acne Vulgaris – Pipeline by Dermata Therapeutics LLC, H1 2020

Acne Vulgaris – Pipeline by Dermavant Sciences Inc, H1 2020

Acne Vulgaris – Pipeline by Devonian Health Group Inc, H1 2020

Acne Vulgaris – Pipeline by Eligo Bioscience SA, H1 2020

Acne Vulgaris – Pipeline by ELORAC Inc, H1 2020

Acne Vulgaris – Pipeline by Gage Development Company LLC, H1 2020

Acne Vulgaris – Pipeline by Galderma SA, H1 2020

Acne Vulgaris – Pipeline by Helix BioMedix Inc, H1 2020

Acne Vulgaris – Pipeline by Innovation Pharmaceuticals Inc, H1 2020

Acne Vulgaris – Pipeline by Johnson & Johnson, H1 2020

Acne Vulgaris – Pipeline by Kalytera Therapeutics Inc, H1 2020

Acne Vulgaris – Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2020

Acne Vulgaris – Pipeline by Melinta Therapeutics Inc, H1 2020

Acne Vulgaris – Pipeline by Menlo Therapeutics Inc, H1 2020

Acne Vulgaris – Pipeline by Mimetica Pty Ltd, H1 2020

Acne Vulgaris – Pipeline by Naked Biome Inc, H1 2020

Acne Vulgaris – Pipeline by Novabiotics Ltd, H1 2020

Acne Vulgaris – Pipeline by Novartis AG, H1 2020

Acne Vulgaris – Pipeline by Origimm Biotechnology GmbH, H1 2020

Acne Vulgaris – Pipeline by Ortho Dermatologics Inc, H1 2020

Acne Vulgaris – Pipeline by Phagelux Inc, H1 2020

Acne Vulgaris – Pipeline by PHI Therapeutics Inc, H1 2020

Acne Vulgaris – Pipeline by Photocure ASA, H1 2020

Acne Vulgaris – Pipeline by Promius Pharma LLC, H1 2020

Acne Vulgaris – Pipeline by Provectus Biopharmaceuticals Inc, H1 2020

Acne Vulgaris – Pipeline by Revive Therapeutics Ltd, H1 2020

Acne Vulgaris – Pipeline by Riptide Bioscience Inc, H1 2020

Acne Vulgaris – Pipeline by Sanotize Research And Development Corp, H1 2020

Acne Vulgaris – Pipeline by Sebela Pharmaceuticals Inc, H1 2020

Acne Vulgaris – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2020

Acne Vulgaris – Pipeline by Sol-Gel Technologies Ltd, H1 2020

Acne Vulgaris – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2020

Acne Vulgaris – Pipeline by Union Therapeutics AS, H1 2020

Acne Vulgaris – Pipeline by Verge Therapeutics Inc, H1 2020

Acne Vulgaris – Pipeline by Vyome Therapeutics Inc, H1 2020

Acne Vulgaris – Dormant Projects, H1 2020

Acne Vulgaris – Dormant Projects, H1 2020 (Contd..1), H1 2020

Acne Vulgaris – Dormant Projects, H1 2020 (Contd..2), H1 2020

Acne Vulgaris – Dormant Projects, H1 2020 (Contd..3), H1 2020

Acne Vulgaris – Dormant Projects, H1 2020 (Contd..4), H1 2020

Acne Vulgaris – Dormant Projects, H1 2020 (Contd..5), H1 2020

Acne Vulgaris – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Acne Vulgaris, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports